CG
CORT icon

Cutler Group’s Corcept Therapeutics CORT Stock Holding History

Cutler Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$11K – 5054
2022
Q1 		$11K Buy
+500
New +$10.6K ﹤0.01% 3527
2019
Q1 		– Sell
-4,036
Closed -$53K – 4115
2018
Q4 		$53K Buy
+4,036
New +$53.3K 0.01% 1439
2018
Q3 		– Sell
-41
Closed – – 4166
2018
Q2 		$0 Hold
41
– – ﹤0.01% 4275
2018
Q1 		$0 Buy
41
+1
+3% +$19 ﹤0.01% 4549
2017
Q4 		$0 Buy
+40
New +$724 ﹤0.01% 5017
2016
Q4 		– Sell
-300
Closed -$1K – 6597
2016
Q3 		$1K Hold
300
– – ﹤0.01% 6054
2016
Q2 		$1K Buy
+300
New +$1.56K ﹤0.01% 6002

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cutler Group's CORT Position: Q2 2022 in Review

Cutler Group sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 500 shares — an estimated $11K sold.

Cutler Group first reported a position in CORT in Q2 2016 and held it in 7 quarters. The position peaked at $53K in Q4 2018. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

  • Cutler Group reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cutler Group sold 500 Corcept Therapeutics shares in Q2 2022, an estimated $11K.
  • Cutler Group first reported a position in Corcept Therapeutics in Q2 2016 and held it in 7 quarters.
  • Cutler Group's Corcept Therapeutics position peaked at $53K in Q4 2018.
  • 225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.